2-arachidonoylglycerol

2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 2-arachidonoylglycerol?

2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol

MeSH term MeSH ID Detail
Acute Pain D059787 3 associated lipids
Acute Lung Injury D055371 33 associated lipids
Fetal Nutrition Disorders D048070 1 associated lipids
Ganglion Cysts D045888 1 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Cholangiocarcinoma D018281 7 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Endometrial Neoplasms D016889 30 associated lipids
Head Injuries, Closed D016489 5 associated lipids
Weight Gain D015430 101 associated lipids
Myocardial Reperfusion Injury D015428 20 associated lipids
Reperfusion Injury D015427 65 associated lipids
Stomach Ulcer D013276 75 associated lipids
Starvation D013217 47 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Pain D010146 64 associated lipids
Obesity D009765 29 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Neuralgia D009437 28 associated lipids
Nervous System Diseases D009422 37 associated lipids
Nerve Degeneration D009410 53 associated lipids
Morphine Dependence D009021 9 associated lipids
Memory Disorders D008569 33 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Inflammation D007249 119 associated lipids
Hypothermia D007035 19 associated lipids
Hypotension D007022 41 associated lipids
Hyperkinesis D006948 11 associated lipids
Hyperinsulinism D006946 27 associated lipids
Hyperalgesia D006930 42 associated lipids
Hepatic Encephalopathy D006501 9 associated lipids
Glioma D005910 112 associated lipids
Fragile X Syndrome D005600 5 associated lipids
Fatty Liver, Alcoholic D005235 11 associated lipids
Epilepsy D004827 35 associated lipids
Encephalitis D004660 15 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Colitis D003092 69 associated lipids
Brain Ischemia D002545 89 associated lipids
Catalepsy D002375 30 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Brain Edema D001929 20 associated lipids
Brain Concussion D001924 5 associated lipids
Body Weight D001835 333 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Alzheimer Disease D000544 76 associated lipids
Per page 10 20 50 100 | Total 51

PubChem Associated disorders and diseases

What pathways are associated with 2-arachidonoylglycerol

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with 2-arachidonoylglycerol?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 2-arachidonoylglycerol?

Knock-out

Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with 2-arachidonoylglycerol

Download all related citations
Per page 10 20 50 100 | Total 1060
Authors Title Published Journal PubMed Link
Venderova K et al. Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus. 2005 Exp. Neurol. pmid:15899265
Kreutz S et al. Cannabinoids and neuronal damage: differential effects of THC, AEA and 2-AG on activated microglial cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures. 2007 Exp. Neurol. pmid:17010339
Zheng G et al. Chronic stress and peripheral pain: Evidence for distinct, region-specific changes in visceral and somatosensory pain regulatory pathways. 2015 Exp. Neurol. pmid:26408049
Mounsey RB et al. Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. 2015 Exp. Neurol. pmid:26244281
Granchi C et al. A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017). 2017 Expert Opin Ther Pat pmid:29053063
van der Stelt M et al. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. 2005 FASEB J. pmid:15894565
DiPatrizio NV et al. Endocannabinoid signaling in the gut mediates preference for dietary unsaturated fats. 2013 FASEB J. pmid:23463697
Bátkai S et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. 2007 FASEB J. pmid:17327359
Siegmund SV et al. The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. 2007 FASEB J. pmid:17440119
Karwad MA et al. The role of CB in intestinal permeability and inflammation. 2017 FASEB J. pmid:28404744
Maestroni GJ The endogenous cannabinoid 2-arachidonoyl glycerol as in vivo chemoattractant for dendritic cells and adjuvant for Th1 response to a soluble protein. 2004 FASEB J. pmid:15385435
Tam J et al. The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. 2008 FASEB J. pmid:17704191
Baker D et al. Endocannabinoids control spasticity in a multiple sclerosis model. 2001 FASEB J. pmid:11156943
Alhouayek M et al. Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. 2011 FASEB J. pmid:21551239
D'Argenio G et al. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. 2006 FASEB J. pmid:16403786
Alhouayek M et al. N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis. 2015 FASEB J. pmid:25384424
Di Marzo V et al. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. 2000 FASEB J. pmid:10877836
Berdyshev EV et al. Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells. 2001 FASEB J. pmid:11641243
Ueda N et al. Metabolism of endocannabinoids and related N-acylethanolamines: canonical and alternative pathways. 2013 FEBS J. pmid:23425575
Bari M et al. In vitro and in vivo models of Huntington's disease show alterations in the endocannabinoid system. 2013 FEBS J. pmid:23659592